Ignite Creation Date:
2024-05-06 @ 7:08 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05908019
Status:
RECRUITING
Last Update Posted:
2023-06-18
First Post:
2023-06-01
Brief Title:
The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management Social Support Activity Tolerance and Quality of Life in Patients With Pulmonary Hypertension
Sponsor:
National Defense Medical Center Taiwan
Organization:
National Defense Medical Center Taiwan
Study Overview
Official Title:
The Effects of Pulmonary Hypertension Web-Based Health Care Program on Symptom Management Social Support Activity Tolerance and Quality of Life in Patients With Pulmonary Hypertension
Status:
RECRUITING
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PAH
Brief Summary:
Pulmonary arterial hypertension PAH is a chronic disease characterized by an elevation in pulmonary artery pressures and pulmonary vascular resistance The condition most often is rarely detected and patients frequently suffer symptoms for several years before being appropriately diagnosed Patients with PH suffer from several symptoms such as exertional dyspnea fatigue weakness chest pain faintinget al Pulmonary hypertension is an incurable and progressive disease with complex symptoms and treatments Patients must learn to deal with their unpredictable future and manage the complex treatments associated with severe adverse effects and need significant changes in lifestyle
Therefore it is important to assist patients to develop the ability of symptom management
Therefore it is important to assist patients to develop the ability of symptom management
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None